SAN DIEGO, Sept. 7, 2017 /PRNewswire/ -- Pfenex Inc.
(NYSE MKT: PFNX), today announced that Dr. Paul Wagner, Chief Financial Officer, is leaving
the Company effective October 13,
2017 to assume another position in industry. Pfenex is
conducting an executive search for a replacement CFO.
Additionally, Steve Sandoval,
Chief Manufacturing Officer, is leaving the Company effective
September 8, 2017, to pursue other
opportunities.
Eef Schimmelpennink, CEO said, "We all wish Paul and Steve all
the best in their new endeavors. I look forward to working
with Paul through the transition and am pleased that he has agreed
to continue supporting the Company as a consultant through the
first quarter of 2018 to further assist in the transition."
Dr. Wagner said, "My time at Pfenex has been rewarding. I have
been particularly honored to have helped build the company
alongside Pfenex's many dedicated employees. I am confident that
Eef and the Pfenex team's focus and capability will help drive
success and build value for our shareholders and I wish them great
success."
About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in
the development of biosimilar therapeutics and high-value and
difficult to manufacture proteins. The company's lead product
candidates are PF708, a therapeutic equivalent candidate to Forteo
(teriparatide) for the treatment of osteoporosis, and PF582, a
biosimilar candidate to Lucentis (ranibizumab), for the potential
treatment of patients with retinal diseases. Pfenex has leveraged
its Pfēnex Expression
Technology® platform to build a pipeline of
product candidates and preclinical products under development
including other biosimilars, as well as vaccines, therapeutic
equivalents to reference listed drug products, and next generation
biologics.
View original content with
multimedia:http://www.prnewswire.com/news-releases/pfenex-announces-management-changes-300516025.html
SOURCE Pfenex Inc.